Expertise in
8
conditions

Dr. Bryan A. Mehlhaff

Urology
Office
2400 Hartman Ln Ste 100, 
Springfield, OR 
Accepting New Patients
Offers Telehealth
Expertise in
8
conditions
Office
2400 Hartman Ln Ste 100, 
Springfield, OR 

Overview

Bryan Mehlhaff is a Urologist practicing medicine in Springfield, Oregon.

Dr. Mehlhaff is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Enlarged Prostate (BPH), Ureteroscopy, and Reconstructive Urology Surgery.

He is actively involved in clinical research, co-authoring 10 peer reviewed articles and participating in 10 clinical trials. Dr. Mehlhaff is currently accepting new patients.

Specialties

Urology

Licenses

Urology in OR

Hospital Affiliations

Mckenzie-Willamette Medical Center
Sacred Heart Medical Center - Riverbend
Mercy Medical Center
Peacehealth Cottage Grove Community Medical Center
Peace Harbor Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
ATRIO Health
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE PART D
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser
  • EPO
  • HMO
  • POS
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Moda Health
  • EPO
  • PPO
PacificSource
  • PPO
Prominence Health
  • EPO
  • PPO
Regence
  • EPO
  • PPO
Samaritan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

Office
2400 Hartman Ln Ste 100, Springfield, OR 97477

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: March 10, 2026
Intervention Type: Drug
Study Drugs: Tazemetostat, Abiraterone/prednisone, Enzalutamide
Study Phase: Phase 1/Phase 2
A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Biological
Study Drugs: Aglatimagene besadenovec, Valacyclovir
Study Phase: Phase 3
A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer
A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Biological, Drug
Study Drugs: Aglatimagene Besadenovec, Valacyclovir
Study Phase: Phase 2
A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment
A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment
Enrollment Status: Completed
Publish Date: October 10, 2024
Intervention Type: Drug
Study Drugs: LAE001, Prednisone, Afuresertib
Study Phase: Phase 1/Phase 2
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
Enrollment Status: Terminated
Publish Date: February 05, 2024
Intervention Type: Drug
Study Drugs: VERU-111, Enzalutamide, Abiraterone, Darolutamide and Apalutamide
Study Phase: Phase 3
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: May 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Registry for Hereditary Cancer Risk Assessment and Genetic Testing Among Men With Prostate Cancer in the Community Urology Practice Setting
A Registry for Hereditary Cancer Risk Assessment and Genetic Testing Among Men With Prostate Cancer in the Community Urology Practice Setting
Enrollment Status: Completed
Publish Date: November 05, 2020
A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer
A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: August 28, 2019
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
Enrollment Status: Terminated
Publish Date: August 19, 2019
Intervention Type: Biological
View 8 Less Clinical Trials

10 Total Publications

Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.
Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.
Journal: The Lancet. Oncology
Published: January 06, 2026
Similar Doctors
Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required

Three Rivers Anesthesia PC

2400 Hartman Ln, 
Springfield, OR 
 (1.6 miles away)
541-334-3350
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Esrig is a Urologist practicing medicine in Springfield, Oregon. Dr. Esrig is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery. Dr. Esrig is currently accepting new patients.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

Three Rivers Anesthesia PC

2400 Hartman Ln, 
Springfield, OR 
 (1.6 miles away)
541-334-3350
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dawn Bodell is a Urologist practicing medicine in Springfield, Oregon. Dr. Bodell is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Urinary Incontinence, Hydronephrosis, UPJ Obstruction, Ureteroscopy, and Bladder Reconstruction. Dr. Bodell is currently accepting new patients.

Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Office

2400 Hartman Ln Ste 100, 
Springfield, OR 
 (0.1 miles away)
541-334-3350
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Woolsey is a Urologist practicing medicine in Springfield, Oregon. Dr. Woolsey is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Familial Prostate Cancer, Prostate Cancer, UPJ Obstruction, Ureteroscopy, and Nephrectomy. Dr. Woolsey is currently accepting new patients.

Frequently Asked Questions about Dr. Bryan A. Mehlhaff

How do I make an appointment with Dr. Bryan A. Mehlhaff?

You can book an appointment with Dr. Bryan A. Mehlhaff by calling their office at 541-484-0926. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Bryan A. Mehlhaff a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Bryan A. Mehlhaff is classified as an Distinguished expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Bryan A. Mehlhaff specialize in?

While Dr. Bryan A. Mehlhaff is a Urology, they have specific expertise in Prostate Cancer, Familial Prostate Cancer, and Enlarged Prostate (BPH). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Urology.

Does Dr. Bryan A. Mehlhaff participate in research or clinical trials?

Yes. Dr. Bryan A. Mehlhaff has published 10 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Bryan A. Mehlhaff's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Bryan A. Mehlhaff accept my insurance?

Dr. Bryan A. Mehlhaff accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 541-484-0926 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mehlhaff's expertise for a condition
ConditionClose
    View All 34 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile